Literature DB >> 26204445

Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia.

Melissa A Lyle1, Eric R Fenstad2, Michael D McGoon2, Robert P Frantz2, Michael J Krowka3, Garvan C Kane2, Karen L Swanson4.   

Abstract

BACKGROUND: A subset of patients with hereditary hemorrhagic telangiectasia (HHT) develops pulmonary hypertension (PH) by mechanisms including pulmonary arterial hypertension, high flow, and elevated pulmonary arterial wedge pressure (PAWP). We aimed to describe echocardiographic and hemodynamic characteristics of patients with coexisting HHT and PH.
METHODS: We conducted a single-center cohort study of patients with confirmed HHT who underwent right-sided heart catheterization (RHC) and transthoracic two-dimensional echocardiography for suspected PH between June 1, 2003 and September 1, 2013 at Mayo Clinic Rochester, Minnesota.
RESULTS: Of 38 patients with confirmed HHT who underwent RHC and echocardiography, 28 (74%) had a mean pulmonary artery pressure (MPAP) ≥ 25 mm Hg. Of those 28, 12 (43%) had pulmonary arterial hypertension. Two patients had normal PAWP and pulmonary vascular resistance (PVR), with PH secondary to either an atrial septal defect or high cardiac flow. Fourteen patients (50%) had elevated PAWP (≥ 15 mm Hg), nine with evidence of high flow. RHC in all 28 patients demonstrated a MPAP of 41 ± 11 mm Hg, PAWP of 17 ± 10 mm Hg, and PVR of 4.5 ± 4.2 Wood units. Echocardiography demonstrated moderate/severe right ventricular dysfunction in nine patients (32%). The presence of PH trended toward worse survival (P = .06).
CONCLUSIONS: PH in patients with HHT occurs by different mechanisms, and there is a trend toward worse survival in patients who develop PH despite the mechanism. The equal predilection toward all subtypes of PH illustrates the necessity of RHC to clarify the hemodynamics.
Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  genetics; hereditary hemorrhagic telangiectasia; hypertension; pulmonary arterial hypertension; pulmonary hypertension

Mesh:

Substances:

Year:  2016        PMID: 26204445     DOI: 10.1378/chest.15-0535

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

Review 1.  ALK1 signaling in development and disease: new paradigms.

Authors:  Beth L Roman; Andrew P Hinck
Journal:  Cell Mol Life Sci       Date:  2017-09-04       Impact factor: 9.261

2.  Severe pulmonary arterial hypertension in a patient with hereditary hemorrhagic telangiectasia and multiple pulmonary and hepatic arteriovenous malformations.

Authors:  Sunitha Aramalla; Srinivas Bhyravavajhala; Bharathi Vanaparty; Ramakrishna Narayanan; Sreekanth Yerram
Journal:  Ann Pediatr Cardiol       Date:  2022-06-14

3.  Pulmonary arteriovenous malformations in children with hereditary hemorrhagic telangiectasia: a longitudinal study.

Authors:  Katie L Mowers; Lynn Sekarski; Andrew J White; R Mark Grady
Journal:  Pulm Circ       Date:  2018-06-19       Impact factor: 3.017

4.  Pulmonary arteriovenous malformations: diagnostic and treatment characteristics.

Authors:  William Salibe-Filho; Bruna Mamprim Piloto; Ellen Pierre de Oliveira; Marcela Araújo Castro; Breno Boueri Affonso; Joaquim Maurício da Motta-Leal-Filho; Edgar Bortolini; Mário Terra-Filho
Journal:  J Bras Pneumol       Date:  2019-06-19       Impact factor: 2.624

5.  The clinical characteristics and long-term prognosis of pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia.

Authors:  Wen Li; Chang-Ming Xiong; Qing Gu; Xiao-Tong Wang; Xiao-Ling Cheng; Li Huang; Tao Yang; Qin Luo; Zhi-Hui Zhao; Xin-Hai Ni; Zhi-Hong Liu; Jian-Guo He
Journal:  Pulm Circ       Date:  2018-02-26       Impact factor: 3.017

6.  Pulmonary hypertension subtypes associated with hereditary haemorrhagic telangiectasia: Haemodynamic profiles and survival probability.

Authors:  Sabine Revuz; Evelyne Decullier; Isabelle Ginon; Nicolas Lamblin; Pierre-Yves Hatron; Pierre Kaminsky; Marie-France Carette; Pascal Lacombe; Anne-Claire Simon; Sophie Rivière; Jean-Robert Harlé; Alain Fraisse; Christian Lavigne; Vanessa Leguy-Seguin; Ari Chaouat; Chahera Khouatra; Sophie Dupuis-Girod; Eric Hachulla
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

Review 7.  Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension.

Authors:  Adam Andruska; Edda Spiekerkoetter
Journal:  Int J Mol Sci       Date:  2018-08-24       Impact factor: 5.923

Review 8.  Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia.

Authors:  Veronique M M Vorselaars; Anna E Hosman; Cornelis J J Westermann; Repke J Snijder; Johannes J Mager; Marie-Jose Goumans; Marco C Post
Journal:  Int J Mol Sci       Date:  2018-10-17       Impact factor: 5.923

Review 9.  The role of genomics and genetics in pulmonary arterial hypertension.

Authors:  Emilia M Swietlik; Stefan Gräf; Nicholas W Morrell
Journal:  Glob Cardiol Sci Pract       Date:  2020-04-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.